The ongoing search for therapeutic interventions in Alzheimer disease (AD) has highlighted
the complexity of this condition and the need for additional biomarkers, beyond amyloid-β …

The accumulation of amyloid-beta peptide (Aβ) and the failure of cholinergic transmission
are key players in Alzheimer's disease (AD). However, in the healthy brain, Aβ contributes to …

It is now recognized that astrocytes participate in synaptic communication through intimate
interactions with neurons. A principal mechanism is through the release of gliotransmitters …

Alzheimer's disease (AD) is the leading cause of dementia affecting over 25 million people
worldwide. Classical studies focused on the description and characterization of the …

Aberrant amyloid-β peptide (Aβ) accumulation along with altered expression and function of
nicotinic acetylcholine receptors (nAChRs) stand prominently in the etiology of Alzheimer's …

Alzheimer's disease (AD) and dementia with Lewy bodies (DLB) are common forms of
dementia in the elderly associated with cholinergic dysfunction, including reductions in …

Background β-amyloid (Aβ) accumulation is described as a hallmark of Alzheimer's disease
(AD). Aβ perturbs a number of synaptic components including nicotinic acetylcholine …

Although there is still no known effective preventative treatment or cure for Alzheimer's
disease (AD), the development of new drugs that target pathological features that appear …

Alzheimer's disease (AD) is one of the major disabling and lethal diseases for aged
individuals worldwide. To date, there are more than 10 hypotheses proposed for AD …

We previously reported that α7 nicotinic acetylcholine receptor (nAChR) agonism produces
efficacy in preclinical cognition models correlating with activation of cognitive and …